Pacific Biosciences Of California (PACB) EPS (Basic) Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.82% |
| Dec 31, 2025 | -17.88% |
| Sep 30, 2025 | 1.47% |
| Jun 30, 2025 | 1.37% |
| Mar 31, 2025 | -170.94% |
| Dec 31, 2024 | 16.70% |
| Sep 30, 2024 | -2.98% |
| Jun 30, 2024 | -31.95% |
| Mar 31, 2024 | -7.71% |
| Dec 31, 2023 | -8.10% |
| Sep 30, 2023 | -6.47% |
| Jun 30, 2023 | -10.49% |
| Mar 31, 2023 | -12.47% |
| Dec 31, 2022 | -16.83% |
| Sep 30, 2022 | -12.34% |
| Jun 30, 2022 | -4.24% |
| Mar 31, 2022 | -7.31% |
| Dec 31, 2021 | -10.53% |
| Jun 30, 2021 | 0.00% |
| Mar 31, 2021 | -14.37% |
| Dec 31, 2020 | 117.79% |
| Sep 30, 2020 | -55.18% |
| Jun 30, 2020 | 1.28% |
| Mar 31, 2020 | 15.29% |
| Dec 31, 2019 | 14.06% |
| Sep 30, 2019 | -7.89% |
| Jun 30, 2019 | 9.94% |
| Mar 31, 2019 | 6.51% |
| Dec 31, 2018 | 3.43% |
| Sep 30, 2018 | 9.33% |
| Jun 30, 2018 | 12.42% |
| Mar 31, 2018 | 11.58% |
| Dec 31, 2017 | 14.86% |
| Sep 30, 2017 | 14.26% |
| Jun 30, 2017 | 8.25% |
| Mar 31, 2017 | 12.26% |
| Dec 31, 2016 | 13.37% |
| Sep 30, 2016 | 18.85% |
| Jun 30, 2016 | 12.94% |
| Mar 31, 2016 | 19.01% |
| Dec 31, 2015 | -14.87% |
| Sep 30, 2015 | 14.88% |
| Jun 30, 2015 | 68.45% |